NCT00092690
Completed
Phase 3
A Multicenter, Double-Blind, Randomized, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Patients With Hypercholesterolemia
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Hypercholesterolemia
- Sponsor
- Organon and Co
- Enrollment
- 1902
- Primary Endpoint
- Plasma LDL-C averaged across all doses after 6 weeks
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
This study is to assess the safety and efficacy of an investigational drug as compared to an approved drug to reduce specific cholesterol levels.
Detailed Description
The duration of treatment is 6 weeks.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Elevated cholesterol
Exclusion Criteria
- •Unstable medical conditions or significant heart problems within 3 months prior to first study visit.
Outcomes
Primary Outcomes
Plasma LDL-C averaged across all doses after 6 weeks
Secondary Outcomes
- Plasma LDL-C for each dose; plasma HDL-C averaged across all doses
Similar Trials
Completed
Phase 2
A Study in Subjects With Perennial Allergic RhinitisPerennial Allergic RhinitisNCT00210015Merck Sharp & Dohme LLC630
Completed
Phase 3
Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025)HypercholesterolemiaNCT00092716Organon and Co655
Completed
Phase 3
Efficacy and Safety Study for the Treatment of Dysfunctional Uterine BleedingMetrorrhagiaNCT00307801Bayer231
Completed
Phase 3
Efficacy and Safety Study for the Treatment of Dysfunctional Uterine BleedingMetrorrhagiaNCT00293059Bayer190
Completed
Phase 3
Effectiveness of Two Approved Drugs in Lowering High Cholesterol (0733-224)HypercholesterolemiaNCT00092157Organon and Co571